Akiram Therapeutics

#Akiram Therapeutics #Immunohistochemistry #Solid tumours

First clinical results from AKIR001 to be presented at EANM 2026 

Akiram Therapeutics’ abstract presenting the first clinical results from the ongoing first-in-human trial has been selected as a Top Rated Oral Presentation (TROP) at EANM 2026. The study is evaluating 177Lu-AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumours who have no remaining standard treatment options. … Read More

#News

Tumour microenvironment
#Akiram Therapeutics #Cancer research #Drug development #Radionuclide therapy #Radiopharmaceuticals #Solid tumours

Partnership supports radiopharmaceutical solid tumour development

Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves… Read More

#News

#Akiram Therapeutics #Clinical trials #Radiotherapy #Sweden

First patient enrolled in Phase I trial of Akiram’s cancer drug

Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More

#Cancer Research #News

Radioactive containers
#Akiram Therapeutics #Events #Immunotherapy #Oncology #Radiopharmaceuticals

Radioimmunotherapy drug results to be shared at EANM

Akiram Therapeutics will reveal its research findings on radioimmunotherapy drug candidate AKIR001 at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from 19-23 October. 177Lu-AKIR001 holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer,… Read More

#News